Sen. Hatch’s Generic Fix: Limits On 180-Day Marketing Exclusivity Proposed
Executive Summary
Sen. Orrin Hatch (R-Utah) is proposing further reforms to Waxman/Hatch that would eliminate the 180-day marketing exclusivity award to the first ANDA filer in certain circumstances
You may also be interested in...
PTO Tougher On Patent Claims Following Claritin Metabolite Ruling – Attorney
Patenting drug claims has become more difficult due to recent court rulings in Waxman/Hatch cases, attorney Anthony Insogna said during a panel discussion at the J.P. Morgan health care conference in San Francisco Jan. 14
PTO Tougher On Patent Claims Following Claritin Metabolite Ruling – Attorney
Patenting drug claims has become more difficult due to recent court rulings in Waxman/Hatch cases, attorney Anthony Insogna said during a panel discussion at the J.P. Morgan health care conference in San Francisco Jan. 14
AHRQ Comparative Trial Funding Awaits Supplemental Appropriation
The comparative trial/cost effectiveness provisions in the Medicare legislation will require a supplemental appropriation for the Agency for Healthcare Research & Quality